Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Jan 15;15(1):e0227532.
doi: 10.1371/journal.pone.0227532. eCollection 2020.

Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: A meta-analysis

Baohui Fu  1 , Yue Ji  1 , Shouci Hu  2 , Tong Ren  1 , Maheshkumar Satishkumar Bhuva  3 , Ge Li  4 , Hongtao Yang  1
Affiliations
Meta-Analysis

Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: A meta-analysis

Baohui Fu et al. PLoS One. .

Abstract

Objectives: To assess the potency of anti-viral treatment for hepatitis B virus-associated glomerulonephritis (HBV-GN). Method: We searched for controlled clinical trials on anti-viral therapy for HBV-GN in MEDLINE, Embase, the Cochrane Library, and PubMed from inception to March 11th 2019. Seven trials, including 182 patients met the criteria for evaluating. The primary outcome measures were proteinuria and changes in the estimated glomerular filtration rate, and the secondary outcome measure was hepatitis B e-antigen clearance. A fixed or random effect model was established to analyze the data. Subgroup analyses were performed to explore the effects of clinical trial type, anti-viral drug type, age, and follow-up duration.

Results: The total remission rate of proteinuria (OR = 10.48, 95% CI: 4.60-23.89, I2 = 0%), complete remission rate of proteinuria (OR = 11.64, 95% CI: 5.17-26.21, I2 = 23%) and clearance rate of Hepatitis Be Antigen (HBeAg) were significantly higher in the anti-viral treatment group than in the control group (OR = 27.08, 95% CI: 3.71-197.88, I2 = 63%). However, antiviral therapy was not as effective regarding the eGFR (MD = 5.74, 95% CI: -4.24-15.73). In the subgroup analysis, age and drug type had significant impacts on proteinuria remission, and study type and follow-up duration only slightly affected the heterogeneity.

Conclusion: Antiviral therapy induced remission of proteinuria and increased HBeAg clearance but failed to improve the eGFR. Pediatric patients were more sensitive to antiviral therapy than adults. IFNs seem more effective but are accompanied by more adverse reactions than NAs.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow chart of study selection.
Fig 2
Fig 2. CR and CR+PR with antiviral therapy in all trials and CCTs.
OR: odds ratio; CR: complete remission; PR: partial remission.
Fig 3
Fig 3. CR and CR+PR with IFNs and NAs in HBV-GN patients.
OR: odds ratio; CR: complete remission.
Fig 4
Fig 4. CR with antiviral therapy in adult patients and pediatric patients.
OR: odds ratio; CR: complete remission.
Fig 5
Fig 5. CR and CR+PR with at the 12-month follow-up.
OR: odds ratio; CR: complete remission; PR: partial remission.
Fig 6
Fig 6. eGFR in antiviral therapy.
OR: odds ratio.
Fig 7
Fig 7. HBeAg clearance in antiviral therapy.
OR: odds ratio.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Collaborators TPO. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403. 10.1016/S2468-1253(18)30056-6 - DOI - PubMed
    1. Zhang X, Liu S, Tang L, Wu J, Chen P, Yin Z, et al. Analysis of pathological data of renal biopsy at one single center in China from 1987 to 2012. Chin Med J (Engl.). 2014;127(9):1715–1720. - PubMed
    1. Andrassy KM. Comments on'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'.Kidney international. 2013;84(3):622–3. - PubMed
    1. Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Alimentary pharmacology & therapeutics. 2006; 24(5):781–788. - PubMed
    1. Khedmat H, Taheri S. Hepatitis B virus-associated nephropathy: an International Data Analysis. Iranian Journal of Kidney Diseases. 2010; 4(2):101 - PubMed

Publication types

MeSH terms

Substances